Cargando…

Prototype of an evidence‐based tool to aid individualized treatment for type 2 diabetes

Data‐driven tools are needed to inform individualized treatment decisions for people with type 2 diabetes (T2D). To show how treatment might be individualized, an interactive outline tool was developed to predict treatment outcomes. Individualized predictions were generated for change in HbA1c and b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buse, John B., Holst, Ingrid, Knop, Filip K., Kvist, Kajsa, Thielke, Desirée, Pratley, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251774/ https://www.ncbi.nlm.nih.gov/pubmed/33764641 http://dx.doi.org/10.1111/dom.14381

Ejemplares similares

Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
por: Klein, Klara R, et al.
Publicado: (2021)

Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley, Richard E
Publicado: (2014)

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2020)

Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE
por: Bergenstal, Richard M., et al.
Publicado: (2023)

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
por: Verma, Subodh, et al.
Publicado: (2019)

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
por: Verma, Subodh, et al.
Publicado: (2020)

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test
por: Holst, Jens J., et al.
Publicado: (2015)

Abstract 4: Derived time-in-range is associated with major adverse cardiovascular event in T2D: Data from the DEVOTE trial
por: Pathan, Muzammil Khan A, et al.
Publicado: (2022)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
por: Leiter, Lawrence A., et al.
Publicado: (2020)

Individual Differences in Auditory Training Benefits for Hearing Aid Users
por: Barda, Ayelet, et al.
Publicado: (2023)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Controlling Lipids AIDS in the Prevention of Type 2 Diabetes, Hypertension, and Cardiovascular Diseases
por: Nayak, Shivananda B., et al.
Publicado: (2017)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone
por: Vilsbøll, Tina, et al.
Publicado: (2016)

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
por: Gluud, Lise L, et al.
Publicado: (2014)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
por: Fotheringham, Amelia K., et al.
Publicado: (2020)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Examination of Factors Affecting the Likelihood of Whether Individuals Would Purchase Cartilage Conduction Hearing Aids
por: Takai, Shunsuke, et al.
Publicado: (2023)

THE ROLE OF MICROFILAMENTS IN FROG SKIN ION TRANSPORT
por: Pratley, James N., et al.
Publicado: (1973)

The Adult Difficult Intravenous Access (DIVA) Cognitive Aid: An Evidence-Based Cognitive Aid Prototype for Difficult Peripheral Venous Access
por: Stagg, Philip L
Publicado: (2023)

A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
por: Junker, Anders Ellekær, et al.
Publicado: (2014)

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
por: Calanna, Salvatore, et al.
Publicado: (2013)

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
por: Pieber, Thomas R., et al.
Publicado: (2017)

Comment on: Chen et al. Utilizing the Second-Meal Effect in Type 2 Diabetes: Practical Use of a Soya-Yogurt Snack. Diabetes Care 2010;33:2552–2554
por: Knop, Filip K.
Publicado: (2011)

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
por: Freemantle, Nick, et al.
Publicado: (2015)

Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012–2019
por: Boye, Kristina S., et al.
Publicado: (2021)

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
por: Pratley, Richard E., et al.
Publicado: (2017)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

A causal roadmap for generating high-quality real-world evidence
por: Dang, Lauren E., et al.
Publicado: (2023)

Translating Evidence to Facilitate Shared Decision Making: Development and Usability of a Consult Decision Aid Prototype
por: Stacey, Dawn, et al.
Publicado: (2016)

The Effect of Different Postprandial Exercise Types on Glucose Response to Breakfast in Individuals with Type 2 Diabetes
por: Bellini, Alessio, et al.
Publicado: (2021)

Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
por: Andersson, Emelie, et al.
Publicado: (2020)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

World AIDS Day 2013: “Getting to Zero: Ending AIDS”
por: Buse, Kent, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4bmucg3isfbudb1qdo7no1sihl